ImmunoGen Inc., a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced a multi-year collaboration to research novel, first-in-class ADCs with Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and ADC-based therapies, utilizing ImmunoGen's proprietary linker-payload technology directed to novel targets identified via OBT's proprietary OGAP
